Kang S, et al. - This study is performed to depict clinical outcomes of etonogestrel implant patients with migration to the vasculature, chest wall, and other distant body sites spontaneously reported to the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. These FAERS case series displays etonogestrel implant migration to the vasculature, chest wall, and other body sites distant from the site of original insertion.

Methods

• They performed a standardized Medical Dictionary for Regulatory Activities (MedDRA) query in the FAERS database (through November 15, 2015) with reports coded with one or more MedDRA preferred terms (PTs) that indicate complications with device placement or migration of the device from the original site of insertion to the vasculature, chest wall and other distant body sites.
• Any cases previously depicted in the medical literature were not included in this study.

Results

• They recognized 38 cases of pronounced etonogestrel implant migration.
• Migration locations included lung/pulmonary artery (n=9), chest wall (n=1), vasculature at locations other than lung/pulmonary artery (n=14), and extravascular migrations (n=14) to other body sites (e.g., axilla, and clavicle/neck line/shoulder).
• The majority of cases were asymptomatic and detected when the patient desired implant removal; however, seven cases reported symptoms such as pain, discomfort, and dyspnea in relationship with implant migration.
• Three cases also depict pulmonary fibrosis and skin reactions as a result of implant migration to the vasculature, chest wall and other distant body sites.
• Sixteen cases reported surgical removal in an operating room setting.